This study is a clinical study to explore the efficacy and safety of BL-B01D1 monotherapy, BL-B01D1 in combination with lenvatinib, BL-B01D1 in combination with PD-1 monoclonal antibody, and BL-B01D1 in combination with PD-1 monoclonal antibody and bevacizumab in patients with advanced hepatocellular carcinoma.
Sign the informed consent form voluntarily and follow the protocol requirements;
Gender is not limited;
Age ≥18 years old and ≤75 years old;
Expected survival time ≥3 months;
Patients with active central nervous system metastases;
Who had participated in any other clinical trial within 4 weeks before the trial dose;
Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;
Had undergone major surgery (investigator-defined) within 4 weeks before the first dose;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator